poisar

Stock

CRISPR Therapeutics AG CRSP

$53.55-0.81%

Overview

CRSP market data

Price History

CRSP price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$6.47
Diluted earnings per share over the trailing twelve months.
Beta
1.78
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3,368.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$44.12 – $78.48
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $5.2B · P/B 2.60 · P/S 389.10.

Company News

10 captured
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88Benzinga · Aug 4, 2026, 3:24 PM
8-K filing — CRISPR Therapeutics AG (CRSP)SEC EDGAR · Aug 3, 2026, 8:24 PM
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M EstimateBenzinga · Aug 3, 2026, 8:18 PM
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.The Motley Fool · Jul 27, 2026, 11:00 AM
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?The Motley Fool · Jul 20, 2026, 6:15 PM
Vertex’s Crinetics Deal Balances Growth with Integration RiskInvesting.com · Jul 8, 2026, 3:01 PM
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price TargetBenzinga · Jul 6, 2026, 12:45 PM
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jul 6, 2026, 12:15 PM
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock